Pyxis Oncology (PYXS) EBITDA (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of EBITDA data on file, last reported at -$18.3 million in Q4 2025.

• On a quarterly basis, EBITDA rose 54.34% year-over-year to -$18.3 million in Q4 2025; TTM through Dec 2025 was -$84.4 million, a 5.63% increase from a year earlier, with the FY2025 full-year figure at -$84.4 million, up 5.63% from the prior year.
• EBITDA for Q4 2025 stood at -$18.3 million, up from -$23.5 million in the prior quarter.
• Over the last five years, EBITDA for PYXS reached as high as -$5.6 million in Q1 2024 and fell as low as -$40.1 million in Q4 2024.
• Historically, EBITDA has averaged -$22.5 million across 5 years, with a median of -$21.9 million in 2023.
• Across the five-year window, EBITDA sank 333.02% in 2022 and surged 73.25% in 2024, its largest moves.
• Year by year, EBITDA stood at -$16.4 million in 2021, then plunged by 131.18% to -$38.0 million in 2022, then soared by 53.21% to -$17.8 million in 2023, then plunged by 125.52% to -$40.1 million in 2024, then soared by 54.34% to -$18.3 million in 2025.
• Per Business Quant data, the three most recent EBITDA figures were -$18.3 million in Q4 2025, -$23.5 million in Q3 2025, and -$19.8 million in Q2 2025.